Royal Philips is set to scale up the production of certain critical care products and solutions to help detect and provide treatment for patients with the coronavirus (Covid-19).
The products include patient vital signs monitors, portable ventilators and medical consumables for non-invasive and invasive ventilation to treat various respiratory conditions.
In addition, the company intends to distribute diagnostic imaging systems, including CT, mobile diagnostic X-ray and hospital telehealth solutions that enable patient monitoring at hospital and home worldwide.
Royal Philips plans to double production of hospital ventilators within the next eight weeks and achieve a four-fold increase by the second half of this year. Its global supplier network is being mobilised to enable the support and production.
Royal Philips CEO Frans van Houten said: “In line with Philips’ mission to improve people’s lives, we want to help as many healthcare providers as possible to deal with the growing numbers of critical Covid-19 patients.
“There is an unprecedented global demand for medical equipment to help diagnose and treat patients with Covid-19.”
To scale up the production, the company is hiring additional manufacturing employees and shifting current employees to support the increasing demand.
Royal Philips is also adding manufacturing lines and increasing the number of shifts.
Furthermore, the company will leverage its innovation capabilities to re-purpose adjacent product ranges to address the increased demand for its products.
Philips has also urged governments to facilitate improved access to critical materials and components by not imposing restrictions such as export controls and tariffs. It has also sought help to accelerate logistics and exemptions from lockdown measures for critical suppliers.
The company has final assembly sites in North America, Europe and Asia and a global network of certified materials and component suppliers.